Jubilant Pharmova Plans Rs. 800 Cr NCD Issuance for Funding
FUNDRAISE
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 12 Oct 2026, 12:38 PM IST · BSE ID: f3ed3ef1-884c-45a9-8bb0-3e84a3280749
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's directors agreed to borrow up to ₹800 crore by selling secured or unsecured bonds to investors.
🤖 AI Summary
- Jubilant Pharmova board approved issuing up to ₹800 crore via NCDs.
- Secured/unsecured NCDs will have a face value of ₹1,00,000 each.
- The issuance will be on a private placement basis in one or more tranches.
- Company will seek member authorization for up to ₹2,500 crore debt issuance.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Aggregate amount of NCDs to be issued
₹800 crore
Face value per NCD
₹1,00,000
Number of NCDs to be issued
80,000
Maximum aggregate outstanding debt securities to be authorized
₹2,500 crore
Tenure of NCDs
Upto five years from the Deemed Date of Allotment
🏢 How This Affects the Company
This issuance provides a mechanism for the company to raise capital for its operations and strategic initiatives.
The NCD issuance will increase the company's debt obligations by up to ₹800 crore initially, impacting its leverage ratios. A broader authorization for up to ₹2,500 crore indicates potential for further debt financing.
The company is increasing its reliance on debt financing, which carries interest payment obligations and repayment risks.
👥 What This Means For Shareholders
✅
Action Required
Shareholders will need to vote on the special resolution for the broader debt issuance via postal ballot.
👤
Who Is Affected
All shareholders will be affected by the increase in the company's debt levels and potential dilution of equity if warrants are issued.
🔍
Management Signal
Management is signaling a proactive approach to capital raising and financing future growth through debt instruments.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Shareholder vote outcome for ₹2,500 crore debt authorization.
Details of the first tranche NCD issuance, including coupon rate.
Company's use of funds from the NCD issuance.
MEDIUM RISK
Increase in debt levels requires careful monitoring of repayment capacity and interest rate fluctuations.
💡 Investor Takeaway
Jubilant Pharmova will issue up to ₹800 crore in secured/unsecured NCDs, with a broader member approval sought for ₹2,500 crore debt issuance within one year.
⚖️ Strengths & Concerns
✅ Positives
- Board approval secured for issuing up to ₹800 crore Non-Convertible Debentures.
- Proposed NCDs to be listed on BSE, providing potential for liquidity.
⚠️ Concerns
- Requires member approval via postal ballot for broader debt issuance authorization.
- Coupon/interest rate to be determined by bidding process.
❓ Frequently Asked Questions
What is the total amount Jubilant Pharmova plans to raise through the NCD issuance?
Jubilant Pharmova's Board approved issuing Non-Convertible Debentures aggregating up to ₹800 crore.
What is the face value of each Non-Convertible Debenture (NCD)?
Each NCD has a face value of ₹1,00,000.
Will these NCDs be listed on the stock exchange?
Yes, the Non-Convertible Debentures are proposed to be listed on the Bombay Stock Exchange Limited (BSE).
What is the maximum amount of debt securities the company is seeking authorization for?
The company is seeking members' authorization for an aggregate amount not exceeding ₹2,500 crore outstanding at any point of time.
What is the maximum tenure for these Non-Convertible Debentures?
The tenure of the instrument is up to five years from the Deemed Date of Allotment.
Questions based on this BSE filing only. For information purposes.